5 unknown, 3 completed, 1 enrolling by invitation, 1 recruiting. 12 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 5, Completed 3, Enrolling by invitation 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Enrolling by invitation 1, Unknown 1 |
Follow Acute Promyelocytic Leukemia: new trials by email Literature Review of Acute Promyelocytic Leukemia trials Research Report on Acute Promyelocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Frontline Oral Arsenic Trioxide for APL Oral Arsenic Trioxide Formulation - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 100 | 2021-01-01 | 2025-06-12 |
| Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Mylotarg, Arsenic Trioxide, All-trans retinoic acid - Acute Promyelocytic Leukemia | Phase 2 | Recruiting | Associazione Italiana Ematologia Oncologia Pediatrica | 89 | 2019-10-09 | 2024-04-15 |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Oral arsenic Trioxide, ATRA and ascorbic acid - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 60 | 2018-08-15 | 2022-10-04 |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Tretinoin and Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2011-07-01 | 2021-11-30 |
| New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia NRX 195183 (retinoid analogue), Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 2 | Withdrawn | University of Southern California | 2010-05-01 | 2015-10-27 | |
| ASCT for Relapsed APL After Molecular Remission autologous hematopoietic cell transplantation - Acute Promyelocytic Leukemia, Relapse | Phase 2 | Terminated | Shanghai Jiao Tong University School of Medicine | 5 | 2009-06-01 | 2014-12-02 |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia NRX 195183 Soft Gelatin Capsule - Acute Promyelocytic Leukemia | Phase 2 | Unknown | NuRx Pharmaceuticals, Inc. | 65 | 2008-04-01 | 2008-05-12 |
| Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Tamibarotene - Acute Promyelocytic Leukemia | Phase 2 | Completed | CytRx | 15 | 2007-09-01 | 2013-02-13 |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin - Acute Promyelocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 78 | 2006-12-01 | 2019-05-07 |
| Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Single agent arsenic trioxide - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Unknown | Christian Medical College, Vellore, India | 400 | 2004-06-01 | 2007-08-17 |
| AIDA 2000 Guidelines all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia | Phase 2 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 600 | 2000-05-01 | 2020-10-14 |
Leukemia, Promyelocytic, Acute (12) · Recurrence (2) · Leukemia (1) · Neoplasms (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Leukemia, Myeloid (12) · Leukemia, Myeloid, Acute (12) · Neoplasms by Histologic Type (12) · Leukemia (11) · Neoplasms (11) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Arsenic Trioxide (5) · Tretinoin (5) · Gemtuzumab (2) · Ascorbic Acid (1) · Idarubicin (1) · tamibarotene (1) · venetoclax (1)
The University of Hong Kong (2) · Associazione Italiana Ematologia Oncologia Pediatrica (1) · Christian Medical College, Vellore, India (1) · CytRx (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · NuRx Pharmaceuticals, Inc. (1) · Shanghai Jiao Tong University School of Medicine (1) · The First Affiliated Hospital of Soochow University (1) · University of Southern California (1)
United States (5) · China (2) · Hong Kong (2) · Italy (2) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · India (1) · Ireland (1) · Israel (1) · Netherlands (1) · Portugal (1)
Dan Douer, MD (1) · Fanco Locatelli, Prof (1) · Farhad Ravandi-Kashani, MD (1) · Harinder Singh Harry Gill, MBBS (1) · Harry Gill, MD (1) · JIong HU, M.D. (1) · Jae Park, MD (1) · Jorge Cortes, MD (1) · Mammen Chandy, MD (1)
2017 (1)